Jeffrey Wolf, MD, Oncology, San Francisco, CA, UCSF Medical Center

JeffreyL.WolfMD

Oncology San Francisco, CA

Hematologic Oncology

Assistant Clinical Professor of Medicine, UCSF

Dr. Wolf is on Doximity

As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Wolf's full profile

Already have an account?

Education & Training

  • UCSF
    UCSFFellowship, Hematology, 1976 - 1978
  • University of California San Diego
    University of California San DiegoResidency, Internal Medicine, 1975 - 1976
  • University of California San Diego
    University of California San DiegoResidency, Internal Medicine, 1972 - 1974
  • University of Illinois College of Medicine
    University of Illinois College of MedicineClass of 1972

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 1973 - 2023
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

  • Regional Top Doctor Castle Connolly, 2014
  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
  • Super Doctor SuperDoctors.com

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • Profiling the Cell Surface Landscape of Proteasome Inhibitor-Treated and _Resistant Multiple Myeloma to Guide Immunotherapy Targeting, Diagnosis, and Biology
    Jeffrey L. Wolf, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Germline Variation Predicts Treatment Response in Multiple Myeloma
    Jeffrey Lee Wolf, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Press Mentions

  • OncLive® Presents State of the Science Summit™: Diagnosis, Management, and Treatment of Multiple Myeloma, and Myeloproliferative Neoplasm
    OncLive® Presents State of the Science Summit™: Diagnosis, Management, and Treatment of Multiple Myeloma, and Myeloproliferative NeoplasmApril 11th, 2018
  • Measurable Residual Disease Could Improve Multiple Myeloma Treatment Decisions
    Measurable Residual Disease Could Improve Multiple Myeloma Treatment DecisionsDecember 8th, 2020

Hospital Affiliations